Drug
Omacor clinical trials
Also written Lovaza, Omacor and omega-3-acid ethyl esters.
- studies test it
- 89
- open now
- 0
- in phase 3
- 17
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
88 studies that test it; most in 2010 (14)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 11 |
| 2008 | 7 |
| 2009 | 13 |
| 2010 | 14 |
| 2011 | 7 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2017 | 11 |
| 2018 | 4 |
| 2019 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 19
- Phase 2
- 32
- Phase 3
- 17
- Phase 4
- 20
- No phase
- 14
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 63
ImmunityBio, Inc. (11) · AstraZeneca (5) · GlaxoSmithKline (4) · Provident Clinical Research (3) · Medical University of Vienna (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Penn State University (2) · Sanford Research (2)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (11) · Avelumab (11) · Bevacizumab (11) · Capecitabine (11) · Cyclophosphamide (11) · Fluorouracil (11) · Leucovorin (11) · Paclitaxel (11)
Studies
Open first, then newest update. How each study uses Omacor is read from its arms, and is right about nine times in ten.
Testing it · 89
- The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac SurgeryTerminatedPhase 2University of Missouri-ColumbiaNCT06434948Written as Omega-3 Ethyl Esters 4 g
- Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current SmokersActive, not recruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT03598309Written as Lovaza®
- An Open-label Extension to Assess the Continued Efficacy of Omacor Plus SimvastatinCompletedPhase 4Provident Clinical ResearchNCT00678743Written as Omacor + simvastatin
- The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal TransplantationCompletedPhase 3Joe ChanNCT03018041Written as Omacor
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as Lovaza
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169790Written as Lovaza
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03175666Written as Lovaza
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167164Written as omega-3-acid ethyl esters
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197584Written as omega-3 acid ethyl esters
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as Lovaza
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167177Written as omega-3-acid ethyl esters
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as Lovaza
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as Lovaza
- Immunonutrition for Diabetic Foot UlcersTerminatedPhase 2/3Prisma Health-MidlandsNCT05281562Written as Lovaza
- QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/2ImmunityBio, Inc.NCT03329248Written as lovaza
- Effects of Prescription Omega-3 on LDL-C in Primary HypercholesterolemiaCompletedPhase 4Provident Clinical ResearchNCT00746811Written as P-OM3
- Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With HypertriglyceridemiaCompletedNot applicableProvident Clinical ResearchNCT01034540Written as POM3
- QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedPhase 1/2ImmunityBio, Inc.NCT03387098Written as lovaza
- Women With Chest Pain and Normal Coronary Arteries StudyTerminatedNot applicableNorthwestern UniversityNCT00743197Written as Lovaza
- Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced InflammationCompletedNot applicablePenn State UniversityNCT01813110Written as 4 g prescription omega-3 concentrate
See all 89 studies that test Omacor →
Given in every arm · 3 — Omacor is usual care beside what is tested
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionRecruitingPhase 2National Cancer Institute (NCI)NCT06195306Written as Omega-3-Acid Ethyl Esters
- Effects of Fish Oil on Post Ablation ArrhythmiasTerminatedPhase 4University of MichiganNCT00791089Written as LOVAZA
- The Effects of Omega-3 Fatty Acids on Aspirin ResistanceCompletedPhase 1/2University of RochesterNCT00771914Written as Lovaza
As the comparator · 1 — what is tested is compared with Omacor
Codes
What other systems call Omacor · ClinicalTrials.gg INT004220
- MeSH (NLM) C405603OmacorOne source NLM
- UNII (FDA) D87YGH4Z0QOMEGA-3-ACID ETHYL ESTERSConfirmed FDA, NLM
- RxNorm 484348One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C405603 | Omacor | One source NLM |
| UNII (FDA) | D87YGH4Z0Q | OMEGA-3-ACID ETHYL ESTERS | Confirmed FDA, NLM |
| RxNorm | 484348 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.